



Chair of Excellence in Cancer Translational Research

The Institute Albert Bonniot (IAB) (<http://iab.ujf-grenoble.fr/fr/>), seeks highly qualified applicants in the field of Cancer Translational Research for a three-year professor position, extendable to a permanent professor position at the University Joseph Fourier and the University Hospital of Grenoble.

The ideal candidate will be a senior scientist, oncologist or biologist (MD and or PhD) with highly recognized expertise in molecular biology applied to cancer. He/She will have an outstanding track record of publication in top-ranked journals. The conducted research should lead to innovative applied results by developing the synergy between the IAB and Grenoble Institute of Cancer Research (<http://girc.ujf-grenoble.fr/fr/>) teams to exploit the full potential of the Grenoble site in clinical aspects, biology, chemistry, physics and numeric science under the frame of a cancer theragnosis project.

This Chair of Excellence financed by University Joseph Fourier, the University Hospital of Grenoble, the Cancéropole LyonAuvergne Rhone Alpes (CLARA) and the « Collectivités Locales » offers an attractive salary, leading to a permanent position in the University and the Hospital, with associated human (Phd students, post doc positions) and technical resources allowing a high level cancer translational project to be set up rapidly. A proficient level in French language is required given the translational projects to be led.

Potential candidates should send a CV and a project proposal before March 29th 2013 (please download application : <http://iab.ujf-grenoble.fr/fr/>). Selected candidates will be interviewed by an international committee in May 2013. The post will commence in September.

For further information please contact :

Christian Brambilla, Head of IAB: christian.brambilla@ujf-grenoble.fr



The IAB is a Research Centre within the University Joseph Fourier in Grenoble and the French National Institute of Health and Medical Research (INSERM), associated to the University Hospital (CHU) of Grenoble, the French Blood Institute (EFS) and the French National Scientific Research Centre (CNRS).

The Albert Bonniot Institute hosts 13 research teams (245 staff), within the Grenoble University Hospital (CHU), and the nearby Biopolis Biotech Center.



The research field of the Albert Bonniot Institute focusses on basic (epi)genetic studies of pathological genomic programming and the main axes of cell signalling. This basic approach is part of translational studies of tumor initiation and progression that are mainly centered on diagnosis and treatment of lung and liver cancer, hematological malignancies and melanoma which are performed by validation of molecular biomarkers, immunological studies and application of nanobiotechnologies.

The research teams participate in bioclinical and epidemiological resource centres, such as the Technological and Biological Resource Centre, the Clinical/Technical Investigation Centre and the Tumor Bank and they share state-of-the-art technological core facilities for photonic microscopy, flow cytometry, small animal imaging and proteomics and high technology animal facilities including numerous animal models. The teams also have access to the structural biology platforms of both the Structural Biology Institute and the European Synchrotron Research Facility. The Albert Bonniot Institute is a founder member of the GIRC: Grenoble Institute of Cancer Research (<http://girc.ujf-grenoble.fr/fr/>) gathering all the clinical and scientific structures involved in cancer research and applications for diagnosis and treatment of cancer patients.

